Key Highlights

  • SOHM shares are trading 21.62% higher on Wednesday, October 28, 2026, at a price below one cent.
  • The last quote confirmed was $0.0008 on August 18, 2026, with a 52-week range of $0.0007 to $0.0021.
  • Market capitalisation was about $2.42 million on roughly 2.90 billion shares outstanding.
  • The company employs about 145 people and was founded in 2005.
  • Its most recent dated announcement on the public record was a white paper on the ABBIE platform on November 6, 2025.

SOHM Penny Stock Surge: Why Are Shares Trading 22% Higher Without a Release?

SOHM (OTC:SHMN) shares are trading 21.62% higher on Wednesday, October 28, 2026, at a price below one cent, which puts the stock among the most active penny stocks of the session. No dated company release accompanied the move, so the activity cannot be tied to an announcement.

The last quote confirmed was $0.0008 on August 18, 2026, when the shares were unchanged on volume of 3 million. At that level a one-tick move equals a large percentage, so a 21.62% gain is a small absolute change. The price and tier should be treated as indicative, since the shares trade on the OTC Markets.

SOHM Business Mix: What Does a Generic Drug Maker Do With Gene Editing?

SOHM, based in Corona, California, develops, manufactures and distributes generic and private label pharmaceutical products in the United States. Its range covers analgesics, antibiotics, anti-cold and anti-inflammatory medicines, over-the-counter products, cosmeceuticals and nutraceuticals, and it also exports. The company was founded in 2005 and has about 145 employees.

Its website lists wellness products such as gummies and nail-care items, a pharmaceutical line including levetiracetam, contract development and manufacturing services, and a biotech division focused on gene editing research.

ABBIE Platform and Coastar Collaboration: What Has SOHM Disclosed Recently?

SOHM describes ABBIE as its patented gene-editing technology. On November 6, 2025 it released a white paper on ABBIE Cas9-guided integrase technology and a cell line for drug discovery, and on November 4, 2025 it published a note on the FDA's evolving gene-editing framework.

Earlier items include a divisional patent allowance in South Korea on September 15, 2025, a relocation to a new facility in Vista, California on September 2, 2025, a report on August 26, 2025 that its dCas12a technology modified human cells, and a new website on July 21, 2025. The company also has a collaboration agreement with Coastar Therapeutics on genome editing using carriers derived from red blood cell membranes.

Market Value and Filing History: How Small Is the Capital Base?

At $0.0008 and roughly 2.90 billion shares, market capitalisation was about $2.42 million, a decline of 43.1% over the year. The 52-week range is $0.0007 to $0.0021. The company's website links an annual report for 2025, though the figures were not stated on the page.

SOHM has previously worked to return to current reporting status with the OTC Markets. A release dated July 26, 2018 said it had filed its 2016 and 2017 annual financials and its first-quarter 2018 report to move toward current status.

What to Watch Next: Platform Updates and Any First Disclosure Behind the Volume

The items to follow are any new ABBIE data or patent news, an update on the Coastar collaboration, and the next financial statements from the Corona-based company. Whether trading volume holds after today's gain, and whether a dated announcement explains it, are the main open questions.